Sorin FY09 Net Revenues Up 7%
Sorin Group has posted net profit of EUR23.2m for the full year 2009, compared to net loss of EUR37.1m for the prior year priod. EBITDA was EUR99.4m, an
ReviR Therapeutics has received a rare paediatric disease designation (RPDD) from the US Food and Drug Administration (FDA) for RTX-117, its investigational oral small-molecule therapy for Charcot-Marie-Tooth disease (CMT).
Novelos said that adding NOV-002 to paclitaxel and carboplatin chemotherapy was not statistically or meaningfully different in terms of efficacy-related endpoints or recovery from chemotherapy toxicity versus chemotherapy